Nucleai and Merck KGaA will collaborate utilizing Nucleai’s AI-powered platform to develop pathology-based biomarkers as companion diagnostics.
Nucleai, a precision medicine company utilising AI-powered image analysis technology to advance novel pathology-based biomarkers development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, established a long-term partnership to use Nucleai’s pathology image analysis and biomarker discovery platform for several Merck clinical stage oncology assets.
Developing novel biomarkers for Merck’s oncology assets with Nucleai’s AI-powered platform
Merck KGaA, Darmstadt, Germany, will use Nucleai’s AI-powered platform for computer vision exploratory research, with the aim to further develop pathology-based biomarkers as companion diagnostics. The partnership will also use Nucleai’s technology to enhance Merck KGaA’s analytical capabilities in Darmstadt, Germany, allowing for faster turnaround time and scalability for forthcoming studies.
Predicting patient response to therapy
Nucleai’s platform analyses tissue images using computer vision and machine learning approaches to model the tumor and immune system’s spatial characteristics, resulting in unique and specific histological biomarkers identification that might aid in predicting patient response to therapy. These biomarkers have the potential to enhance cancer biology by allowing for more precise classification of responder and non-responder patient populations, as well as clinical trial and patient care success rates. Nucleai draws on patented pathology imaging and clinical data databases from top hospitals and Health Maintenance Organizations (HMOs) in the U.S and Israel.
Avi Veidman, CEO and Co-Founder of Nucleai commented:
“We are thrilled to announce another major collaboration with a leading pharmaceutical company like Merck KGaA, Darmstadt, Germany to identify and develop novel biomarkers for their oncology assets. By combining real world and clinical trial datasets, with an integrated and scalable technology platform, we are harnessing the power of AI and big data and setting the standard for future precision medicine collaborations.”
Nucleai is a precision medicine company that has developed an AI-powered image analysis platform to unlock the power of spatial biology from pathology images. Nucleai’s ATOM platform, built and trained off large-scale proprietary datasets, leverages computer vision and deep neural networks to structure and characterize tissue and cell architecture in pathology images to identify spatial characteristics that predict response to therapy and inform treatment decisions. We are currently partnered with leading pharmaceutical companies to discover novel spatial biomarkers, develop pathology-based companion diagnostics assays and drive improved patient outcomes.
For more information, please visit www.nucleaimd.com.